While Alzheimer's disease is the most common type of dementia, there's another variation that is also relatively prevalent.
Cognition Therapeutics announces promising Phase 2 trial results for CT1812 in dementia with Lewy bodies, with plans for late-stage trials. Cognition Therapeutics, Inc. announced promising topline ...
The phase 2 SHIMMER trial enrolled 130 patients with dementia with Lewy bodies who received either a 100-mg or a 300-mg dose ...
Lewy body dementia – a broad term which includes ‘dementia with Lewy bodies’ and Parkinson’s dementia – can cause delusional ...
Improvements Across Measures of Behavior, Function, Cognition and Movement -- Expediting Plans to Advance CT1812 into Late-Stage Trials -- Full ...
David Gergen was recently diagnosed with Lewy body dementia. His daughter, Katherine Gergen Barnett, reveals the wisdom she ...
B. Riley analyst Mayank Mamtani upgraded Cognition Therapeutics (CGTX) to Buy from Neutral with a price target of $1.50, up from $1. The ...
“Lewy body dementia can be caused by a condition called ‘dementia with Lewy bodies’ (DLB), where a certain protein builds up in parts of the brain that affect thinking and mood. It then ...